Quantcast

Latest Sirolimus Stories

2011-07-29 14:38:29

Combination of two immunosuppressive drugs led to less organ rejection, better organ health after transplant For the thousands of patients who receive kidney transplants in the United States each year, preventing organ rejection without compromising other aspects of health requires a delicate balance of medications. Immunosuppresive drugs that protect transplanted organs can also cause serious side effects, including compromising patients' immunity to infection, cancer, and other threats....

2011-07-26 12:10:00

DURHAM, N.C., July 26, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed patient enrollment in its DESSOLVE II CE Mark clinical study of the MiStent® Drug-Eluting Coronary Stent System. The MiStent DES is an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Enrollment of 183 patients across 26 study centers throughout Europe and New Zealand was accomplished ahead of schedule. Micell...

2011-07-18 10:46:00

HONG KONG, July 18, 2011 /PRNewswire/ -- Data from high-risk patients requiring early discontinuation of dual antiplatelet therapy (DAPT) due to nondeferrable, non-cardiac surgery show good short- and long-term clinical and safety outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online on the journal Minerva Cardioangiologica's website. In the single-center study, patients treated with the Genous endothelial progenitor cell (EPC) capture stent...

2011-07-11 14:08:00

HONG KONG, July 11, 2011 /PRNewswire/ -- OrbusNeich today announced that data from an ex vivo arteriovenous (AV) shunt model of human circulating blood, in addition to results from three preclinical studies, demonstrated that the Genous Stent effectively captures circulating CD34+ endothelial progenitor cells (EPCs) leading to accelerated re-endothelialization and decreased thrombogenicity compared to bare metal stents (BMS). These mechanistic data were published as an e-publication on the...

2011-07-08 00:19:00

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date...

b1c1be76beeda9b7cfcf58a73b7ce5e8
2011-06-30 12:30:00

Scientists have discovered a drug they believe can reverse the effects of premature aging and could extend human life by over a decade. Rapamycin was created from a chemical found in the soil on Easter Island, which is one of the most remote places on Earth and 2,000 miles off the coast of Chile. The drug, which has been nicknamed the "forever young" drug, was used in experiments on children suffering from Hutchinson-Gilford Progeria Syndrome (HGPS).  HGPS is a rare condition in which...

2011-06-29 07:00:00

DURHAM, N.C., June 29, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the MiStent Drug-Eluting Coronary Stent System ("MiStent DES"), an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Based on results observed in the DESSOLVE I trial, Micell has reduced the sample size in its DESSOLVE...

2011-06-15 08:01:00

NEW BRUNSWICK, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation. The restructuring charge will be treated as a special item. In its separate news release today, Cordis announced the discontinuation of its clinical development program for...

2011-06-15 08:00:00

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus...

2011-05-19 10:42:00

PARIS, May 19, 2011 /PRNewswire/ -- OrbusNeich announced that data from multiple clinical trials supporting the safety and efficacy of the Genous Stent in cases where prolonged dual antiplatelet therapy (DAPT) is not advisable were featured today during the HEALING Symposium titled "How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy" at EuroPCR 2011 in Paris. Presenters discussed current treatment alternatives to drug eluting stents...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related